β-羟高铁血红素形成抑制活性很可能具有化学结构、官能团类型的选择关联性，羟基尤其是酚羟基为β-羟高铁血红素形成抑制实验的主要活性基团(肖朝江等, 2016)。近年来有研究显示，含有多个酚羟基的黄酮类成分芹菜素具有显著的体内抗疟活性，其体内抑制伯氏疟原虫(Plasmodiumberghei)的活性在70 mg·kg-1·day-1时可达到70%，效果十分显著(Amiri et al., 2018)；本研究对芹菜素的研究结果表明，该化合物抑制β-羟高铁血红素形成的活性十分显著，其IC50达到168 μg·mL-1，从一个侧面反映了β-羟高铁血红素形成抑制活性与酚羟基以及体内抗疟活性之间的内在联系，对本研究中活性最好的两种植物样品的HPLC分析结果显示，其主成分均应是酚性成分，这进一步印证了上述联系，值得深入研究。

分析本研究结果发现，供试的30种植物中有19个植物具有不同程度的β-羟高铁血红素形成抑制活性，显示出潜在的抗疟活性。这些活性植物醇提物的β-羟高铁血红素形成抑制活性总体弱于相应水提物的活性，提示抗疟活性较好的化合物可能为水溶性的、极性偏大的物质。本研究30种供试植物涵盖了21个科29个属，在植物科属分类范畴方面跨度较大，具有较高的代表性。所筛选出来的活性植物涉及17个科、19个属，进一步证实了从天然产物中发现奎宁、青蒿素等抗疟药物的合理性，以及今后从中发现新型抗疟先导化合物的可行性。因此，本研究为寻找、开发植物来源的新型抗疟天然产物奠定了一定的基础，并在一定程度上为进一步研究上述供试植物提供了参考。

AMIRI M, NOURIAN A, KHOSHKAM M, et al., 2018. Apigenin inhibits growth of thePlasmodiumbergheiand disrupts some metabolic pathways in mice [J]. Phytother Res, 32(9): 1795-1802.

BIRKETT AJ, MOORTHY VS, LOUCQ C, et al., 2013. Malaria vaccine R & D in the decade of vaccines: Breakthroughs, challenges and opportunities [J]. Vaccine, 31(Suppl. 2): B233-B243.

CHONG CR, SULLIVAN JR DJ, 2003. Inhibition of heme crystal growth by antimalarials and other compounds: Implications for drug discovery [J]. Biochem Pharmacol, 66(11): 2201-2212.

DAS P K, GOSWAMI S, CHINNIAH A, et al., : Traditional uses and recent findings [J]. J Ethnopharmacol, 110(2): 189-199.

IMWONG M, SUWANNASIN K, KUNASOL C, et al., 2017. The spread of artemisinin-resistantPlasmodiumfalciparuminthe Greater Mekong subregion: A molecular epidemiology observational study [J]. Lancet Infect Dis, 17(5): 491-497.

JAMPILEK J, 2017. Design of antimalarial agents based on natural products [J]. Curr Org Chem, 21(18): 1824-1846.

KAYSER O, KIDERLEN AF, CROFT SL, 2002. Natural pro-ducts as potential antiparasitic drugs [J]. Stud Nat Prod Chem, 26(Part G): 779-848.

MATUSCHEWSKI K, 2017. Vaccines against malaria—still a long way to go [J]. Febs J, 284(16): 2560-2568.

MISHRA S, AERI V, 2017. Biotransformation of lignan glycoside to its aglycone byWoodfordiafruticosaflowers: Quantification of compounds using a validated HPTLC method [J]. Pharm Biol, 55(1): 360.

MOJAB F, 2012. Antimalarial natural products: A review [J]. Avicenna J Phytomed, 2(2): 52-62.

OKUDA T, YOSHIDA T, HATANO T, et al., 2006. Fractionation of pharmacologically active plant polyphenols by centrifugal partition chromatography [J]. J Liq Chromatogr, 13(18): 3637-3650.

ORJIH A, BANYAL H, CHEVLI R, et al., 1981. Hemin lyses malaria parasites [J]. Science, 214(4521): 667-669.

PAGOLA S, STEPHENS PW, BOHLE DS, et al., 2000. The structure of malaria pigment β-haematin [J]. Nature, 404(6775): 307-310.

POHLIT AM, LIMA RBS, FRAUSIN G, et al., 2013. Amazonian plant natural products: Perspectives for discovery of new antimalarial drug leads [J]. Molecules, 18(8): 9219-9240.

PRICE RN, VON SEIDLEIN L, VALECHA N, et al., 2014. Global extent of chloroquine-resistantPlasmodiumvivax: A systematic review and meta-analysis [J]. Lancet Infect Dis, 14(10): 982-991.

SLATER AFG, SWIGGARD WJ, ORTON BR, et al., 1991. An iron-carboxylate bond links the heme units of malaria pigment [J]. Proc Natl Acad Sci USA, 88(2): 325-329.

VANGAPANDU S, JAIN M, KAUR K, et al., 2007. Recent advances in antimalarial drug development [J]. Med Res Rev, 27(1): 65-107.

WORLD HEALTH ORGANIZATION, 2010. Guidelines for the treatment of malaria: 2nd ed [S]. Geneva: World Health Organization.

WORLD HEALTH ORGANIZATION, 2015. Guidelines for the treatment of malaria: 3rd ed [S]. Geneva: World Health Organization.

WORLD HEALTH ORGANIZATION, 2017a. World Malaria Report 2017 [R]. Geneva: World Health Organization.

WORLD HEALTH ORGANIZATION, 2017b. Artemisinin and artemisinin-based combination therapy resistance [R]. Geneva: World Health Organization.

XIAO CJ, DONG X, HAN BY, et al., 2016. Antimalarial activity ofIsodonyuennanensis[J]. Chin Pharm J, 51(8): 612-615. [肖朝江， 董相， 韩冰洋, 等, 2016. 药用植物不育红抗疟活性研究 [J]. 中国药学杂志, 51(8): 612-615.]

文章来源：《植物学报》 网址: http://www.zwxbzz.cn/qikandaodu/2021/0412/1003.html

上一篇：牛奶和豆浆究竟哪个好
下一篇：贫困农村土壤植物儿童人体必需微量元素的研究